Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.

BACKGROUND & AIMS Clinical trials of Crohn's disease generally use the Crohn's Disease Activity Index to assess disease activity; these calculations are complex, time-consuming, and impracticable. We investigated whether a simpler tool, the Harvey-Bradshaw Index, was equally effective in assessing disease severity. METHODS Crohn's Disease Activity and Harvey-Bradshaw Index scores were collected from 2 large multicenter Crohn's disease studies. The PEGylated antibody fragment evaluation in Crohn's disease: safety and efficacy (PRECiSE) 1 and 2 trials assessed efficacy and tolerability of certolizumab pegol (PEGylated, humanized, Fab' fragment of an antitumor necrosis factor alpha antibody). PRECiSE 1 and 2 data were analyzed to determine if results from the Crohn's Disease Activity Index correlated with those from the Harvey-Bradshaw Index criteria for defining response and remission. RESULTS Analysis of almost 1000 data pairs showed a positive correlation between scores. The correlation between the indices for pooled data from PRECiSE 1 and PRECiSE 2 was 0.800 (Spearman correlation coefficient). The correlations between indices for the PRECiSE 1 or PRECiSE 2 were 20.698 and 0.716, respectively (Kronecker product variance). A 3-point change in the Harvey-Bradshaw Index score corresponded to a 100-point change in the Crohn's Disease Activity Index (clinical response); scores < or =4 points corresponded to a Crohn's Disease Activity Index score < or =150 points (clinical remission). CONCLUSIONS Results from the Crohn's Disease Activity Index correlate with those from the Harvey-Bradshaw Index; use of the Harvey-Bradshaw Index might permit simpler Crohn's disease activity assessment in long-term clinical trials, and facilitate standardized disease activity measurements and cross-center comparisons.

[1]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[2]  P. J. Kelly,et al.  Inflammatory bowel disease: epidemiology and management in an English general practice population , 2000, Alimentary pharmacology & therapeutics.

[3]  C. Navascués,et al.  [Incidence and prevalence of inflammatory bowel disease in Gijon, Asturias, Spain]. , 2000, Gastroenterologia y hepatologia.

[4]  W. Best.  Predicting the Crohn's disease activity index from the harvey‐bradshaw index , 2006, Inflammatory bowel diseases.

[5]  Rhodes,et al.  Open label trial of oral clarithromycin in active Crohn’s disease , 2000, Alimentary pharmacology & therapeutics.

[6]  A. Lapidus.  Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. , 2006, World journal of gastroenterology.

[7]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[8]  B. Sands,et al.  A Survey of Methodological Variation in the Crohn's Disease Activity Index , 2005, Inflammatory bowel diseases.

[9]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[10]  C. Brensinger,et al.  A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. , 2004, Gastroenterology.

[11]  R. Modigliani,et al.  Methotrexate for the treatment of refractory Crohn's disease. , 1996, Alimentary pharmacology & therapeutics.

[12]  H. Sørensen,et al.  Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002 , 2006, European journal of gastroenterology & hepatology.

[13]  D. Isenberg,et al.  Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. , 2002, Rheumatology.

[14]  A. Lavie,et al.  A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. , 1995, Journal of clinical gastroenterology.

[15]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[16]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.

[17]  William J. Tremaine,et al.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 , 2007, Inflammatory bowel diseases.

[18]  I. Brandslund,et al.  How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? , 2005, Clinical chemistry and laboratory medicine.

[19]  R. Modigliani,et al.  Methotrexate in Crohn's disease: long-term efficacy and toxicity. , 2000 .

[20]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[21]  G. Kollias,et al.  A new generation of high-affinity humanized PEGylated Fab´ fragment anti-tumor necrosis factor-α monoclonal antibodies , 2006 .

[22]  O. Dewit,et al.  [Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate]. , 2002, Gastroenterologie clinique et biologique.

[23]  J. Lennard-jones,et al.  Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). , 1996, Gut.

[24]  J. Hugot,et al.  A Prospective Study of the Efficacy and Tolerance of a Chimeric Antibody to Tumor Necrosis Factors (Remicade) in Severe Pediatric Crohn Disease , 2003, Journal of pediatric gastroenterology and nutrition.

[25]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[26]  H. Steinhart,et al.  Combination ciprofloxacin and metronidazole for active Crohn's disease. , 1998, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.